PDCD1 and melanoma: The combination therapy with anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody and anti-PD-1 antibody was approved for use for unresectable malignant melanoma by the FDA in America in 2015 [19, 20].